| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abaloparatide |
06.06.01 |
Formulary
|
NICE TA991: Abaloparatide for treating osteoporosis after menopause |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abrocitinib |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Adalimumab |
11.10 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Formulary
|
NIE TA146: Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Adefovir Dipivoxil |
05.03.03 |
Formulary
|
NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Adrenaline |
03.04.03 |
Formulary
|
NICE NG134: Anaphylaxis: assessment and referral after emergency treatment |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264 - Alteplase for treating acute ischaemic stroke |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anakinra |
10.01.03 |
Formulary
|
NICE TA685: Anakinra for treating Still’s disease |
| Andexanet alfa |
02.08.02 |
Formulary
|
NICE TA697- Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
| Asfotase alfa |
09.08.01 |
Formulary
|
NICE: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Ataluren |
10.02 |
Formulary
|
NICE:Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene |
| Atogepant |
04.07.04.02 |
Formulary
|
NICE TA973: Atogepant for preventing migraine |
| Avacopan |
08.02.02 |
Formulary
|
NICE TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis |
| Avalglucosidase alfa |
09.08.01 |
Formulary
|
NICE TA821: Avalglucosidase alfa for treating Pompe disease |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia |
| Azelastine and fluticasone |
12.02.01 |
Formulary
|
NICE: Allergic rhinitis |
| Baricitinib |
13.05.03 |
Formulary
|
NICE TA926: Baricitinib for treating severe alopecia areata |
| Baricitinib |
13.05.03 |
Formulary
|
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis |
| Baricitinib |
05.03 |
Formulary
|
NICE NG191: COVID-19 rapid guideline: managing COVID-19 |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Belimumab |
10.01 |
Formulary
|
NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal) |
| Belimumab |
10.01 |
Formulary
|
NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bempedoic acid with Ezetimibe |
02.12 |
Formulary
|
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Berotralstat dihydrochloride |
03.04.03 |
Formulary
|
NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema |
| Bimekizumab |
13.05.03 |
Formulary
|
NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
| Bimekizumab |
10.01.03 |
Formulary
|
NICE TA918: Bimekizumab for treating axial spondyloarthritis |
| Bimekizumab |
10.01.03 |
Formulary
|
NICE TA916: Bimekizumab for treating active psoriatic arthritis |
| Birch bark extract |
13.01 |
Formulary
|
NICE: Birch bark extract for treating epidermolysis bullosa |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE NG185: Acute coronary syndromes |
| Bivalirudin |
02.08.01 |
Non Formulary
|
NICE CG 94:Unstable angina and NSTEMI |
| Bivalirudin |
02.08.01 |
Non Formulary
|
NICE TAG 230 : Bivalirudin for the treatment of STEMI, 2011 |
| Bosentan |
02.05.01 |
Non Formulary
|
NICE NG167: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders |
| Bosentan |
02.06.04 |
Formulary
|
NICE NG167: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders |
| Botulinum toxin type A |
01.02 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA820: Brolucizumab for treating diabetic macular oedema |
| Budesonide |
01.05.02 |
Formulary
|
NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy |
| Budesonide orodispersible tablets (Jorveza) |
01.05.02 |
Formulary
|
NICE TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis |
| Bulevirtide |
05.03.03 |
Formulary
|
NICE TA896: Bulevirtide for treating chronic hepatitis D |
| Burosumab |
06.06.02 |
Formulary
|
NICE TA993: Burosumab for treating X-linked hypophosphataemia in adults |
| Cabotegravir |
05.03.01 |
Formulary
|
NICE TA757: Cabotegravir with rilpivirine for treating HIV-1 |
| Caffeine citrate |
03.05.01 |
Formulary
|
NICE NG124: Specialist neonatal respiratory care for babies born preterm |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144: Cannabis-based medicinal products |
| Caplacizumab |
09.01.04 |
Formulary
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
| Carbetocin |
07.01.01 |
Formulary
|
NICE NG235: Intrapartum care |
| Cenobamate |
04.08.01 |
Formulary
|
NICE TA753: Cenobamate for treating focal onset seizures in epilepsy |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Cetirizine |
03.04.01 |
Formulary
|
NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine |
| Ciclosporin 0.1% eye drops |
11.11 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cilostazol |
02.06.04 |
Formulary
|
NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clomifene Citrate |
06.05.01 |
Formulary
|
NICE CG156: Fertility problems: assessment and treatment |
| Clonidine Hydrochloride |
02.05.02 |
Formulary
|
NICE NG136: Hypertension in adults: diagnosis and management |
| Clopidogrel |
02.09 |
Formulary
|
NICE NG185: Acute coronary syndromes |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210- Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate |
05.01.07 |
Formulary
|
NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Cyanocobalamin |
09.01.02 |
Formulary
|
NICE NG239: Vitamin B12 deficiency in over 16s: diagnosis and management |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dalteparin |
02.08.01 |
Formulary
|
NICE HST28: Birch bark extract for treating epidermolysis bullosa |
| Danicopan |
09.01.03 |
Formulary
|
NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA775: Dapagliflozin for treating chronic kidney disease |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
02.05.05 |
Formulary
|
NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction |
| Dapagliflozin |
02.05.05 |
Formulary
|
NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis |
| Daridorexant |
04.01.01 |
Formulary
|
NICE TA922: Daridorexant for treating long-term insomnia |
| Darvadstrocel |
01.07.04 |
Non Formulary
|
NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Desmopressin injection |
06.05.02 |
Formulary
|
NICE CG111: Bedwetting in under 19s |
| Desmopressin tablets and spray |
06.05.02 |
Formulary
|
NICE CG111: Bedwetting in under 19s |
| Deucravacitinib |
13.05.03 |
Formulary
|
NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Difelikefalin |
13.03 |
Formulary
|
NICE TA890: Difelikefalin for treating pruritus in people having haemodialysis |
| Dimethyl Fumarate |
13.05.02 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dinoprostone |
07.01.01 |
Formulary
|
NICE NG207: Inducing labour |
| Dipyridamole |
02.09 |
Formulary
|
NICE NG128: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
| Dipyridamole |
02.09 |
Formulary
|
NICE TA210- Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Diroximel Fumarate |
08.02 |
Formulary
|
NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation Link Shared Care Guideline: Amiodarone and Dronedarone |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA955: Dupilumab for treating moderate to severe prurigo nodularis |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Eladocagene exuparvovec |
09.08 |
Formulary
|
NICE: Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency |
| Elafibranor |
01.09.01 |
Formulary
|
NICE TA1016: Elafibranor for previously treated primary biliary cholangitis |
| Elbasvir with grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA382: Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune thrombocytopenia |
| Eluxadoline |
01.02 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA942: Empagliflozin for treating chronic kidney disease |
| Empagliflozin |
02.05.05 |
Formulary
|
NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction |
| Empagliflozin |
02.05.05 |
Formulary
|
NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction |
| Enalapril |
02.05.05.01 |
Formulary
|
NG133: Hypertension in pregnancy: diagnosis and management |
| Enoximone injection |
02.01.02 |
Formulary
|
NICE TA927:Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
| Entecavir |
05.03.03 |
Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Epcoritamab |
08.01.05 |
Formulary
|
NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
| Eplerenone |
02.02.03 |
Formulary
|
NG106: Chronic heart failure in adults: diagnosis and management |
| Eptinezumab |
04.07.04.02 |
Formulary
|
NICE TA871: Eptinezumab for preventing migraine |
| Erenumab |
04.07.04.02 |
Formulary
|
NICE TA682: Erenumab for preventing migraine |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Etrasimod |
01.05.03 |
Formulary
|
NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA800: Faricimab for treating wet age-related macular degeneration |
| Faricimab |
11.08.02 |
Formulary
|
NICE TA799: Faricimab for treating diabetic macular oedema |
| Fenfluramine |
04.08.01 |
Formulary
|
NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome |
| Filgotinib |
10.01.03 |
Formulary
|
NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis |
| Filgotinib |
01.05.03 |
Formulary
|
NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis |
| Finerenone |
02.02.03 |
Formulary
|
NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes |
| Finerenone |
06.01.05 |
Formulary
|
NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA953: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema |
| Fondaparinux |
02.08.01 |
Formulary
|
NICE NG185: Acute coronary syndromes |
| Foslevodopa–Foscarbidopa |
04.09.01 |
Formulary
|
NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms |
| Fostamatinib |
09.01.04 |
Formulary
|
NICE TA935: Fostamatinib for treating refractory chronic immune thrombocytopenia |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA764: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659: Galcanezumab for preventing migraine |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glencaprevir with pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| Glibenclamide |
06.01.02.01 |
Formulary
|
Diabetes in pregnancy: management from preconception to the postnatal period |
| Glycopyrrolate/ indacaterol inhaler |
03.01.04 |
Non Formulary
|
NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler) |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
| Guselkumab |
10.01.03 |
Formulary
|
NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Helicobacter pylori eradication |
01.03 |
Formulary
|
NICE NG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Holoclar |
11.11 |
Formulary
|
NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns |
| Hydralazine |
02.05.01 |
Formulary
|
NG106: Chronic heart failure in adults: diagnosis and management |
| Icosapent ethyl |
02.12 |
Formulary
|
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides |
| Iloprost injection |
02.05.01 |
Non Formulary
|
NICE: review of evidence |
| Iloprost nebuliser solution |
02.06.04 |
Formulary
|
NICE TA918:Bimekizumab for treating axial spondyloarthritis |
| Iloprost nebuliser solution |
02.06.04 |
Formulary
|
NICE TA916: Bimekizumab for treating active psoriatic arthritis |
| Imlifidase |
08.02 |
Formulary
|
NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease |
| Inclisiran |
02.12 |
Formulary
|
NICE TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Indapamide |
02.02.01 |
Formulary
|
NG136: Hypertension in adults: diagnosis and management |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for the treatment of adults with psoriasis |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Iptacopan |
09.01.03 |
Formulary
|
NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE: Stable angina: management |
| Ivacaftor–Tezacaftor–Elexacaftor |
03.07 |
Formulary
|
NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Ivermectin cream 1% |
13.06 |
Formulary
|
NICE: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream |
| Ixekizumab |
13.05.02 |
Formulary
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Ixekizumab |
13.05.02 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA718: Ixekizumab for treating axial spondyloarthritis |
| Labetalol |
02.04 |
Formulary
|
NICE: Hypertension in pregnancy: diagnosis and management |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Latanoprost - Netarsudil eyedrops |
11.06 |
Formulary
|
NICE TA1009: Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension |
| Lebrikizumab |
13.05.03 |
Formulary
|
NICE TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Linaclotide |
01.06.07 |
Formulary
|
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management |
| Linzagolix |
06.07.02 |
Formulary
|
NICE TA996: Linzagolix for treating moderate to severe symptoms of uterine fibroids |
| Liraglutide |
04.05.01 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Loperamide |
01.04.02 |
Formulary
|
NICE: Short bowel syndrome |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor/Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lumacaftor–Ivacaftor |
03.07 |
Formulary
|
NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Lumasiran |
10.01.04 |
Formulary
|
NICE: Lumasiran for treating primary hyperoxaluria type 1 |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Magnesium Glycerophosphate |
09.05.01.03 |
Formulary
|
NICE: Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate |
| Mannitol |
03.07 |
Formulary
|
NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis |
| Maribavir |
05.03.02.02 |
Formulary
|
NICE TA860: Maribavir for treating refractory cytomegalovirus infection after transplant |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
| Metformin |
06.01.02.02 |
Formulary
|
NICE: Type 2 diabetes: prevention in people at high risk |
| Methyldopa |
02.05.02 |
Formulary
|
NG133: Hypertension in pregnancy: diagnosis and management |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE: Multiple Sclerosis; management in primary and secondary care. |
| Metolazone |
02.02.01 |
Formulary
|
NICE TA932: Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) |
| Mexiletine hydrochloride |
10.02.02 |
Formulary
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
| Mifepristone |
07.01.02 |
Formulary
|
NICE NG140: Abortion care |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for treating symptoms of overactive bladder |
| Mirikizumab |
01.05.03 |
Formulary
|
NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis |
| Misoprostol |
07.01.01 |
Formulary
|
NICE NG140: Abortion care |
| Molnupiravir |
05.03 |
Formulary
|
NICE NG191: COVID-19 rapid guideline: managing COVID-19 |
| Momelotinib |
08.01.05 |
Formulary
|
NICE TA957: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Naftidrofuryl oxalate |
02.06.04 |
Formulary
|
NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Naldemedine tosylate |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for treating opioid-induced constipation |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Naltrexone for the management of opioid dependence |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis |
| Nicorandil |
02.06.03 |
Formulary
|
NICE: Stable angina: management |
| Nifedipine |
02.06.04 |
Formulary
|
NICE NG133: Hypertension in pregnancy: diagnosis and management |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
03.11 |
Formulary
|
NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted |
| Nintedanib |
03.11 |
Formulary
|
NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab |
05.03 |
Formulary
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Nirmatrelvir with Ritonavir |
05.03 |
Formulary
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Nusinersen |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA699: Ofatumumab for treating relapsing multiple sclerosis |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating severe persistent allergic asthma |
| Omalizumab |
13.05.03 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
13.05.03 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omega-3-Acid Ethyl Esters |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Omega-3-Marine Triglycerides |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Onasemnogene abeparvovec |
10.02 |
Formulary
|
NICE: Onasemnogene abeparvovec for treating spinal muscular atrophy |
| Onasemnogene abeparvovec |
10.02 |
Formulary
|
NICE: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy |
| Ondansetron |
04.06 |
Formulary
|
NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Ozanimod |
01.05.03 |
Formulary
|
NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis |
| Ozanimod |
08.02 |
Formulary
|
NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis |
| Ozanimod |
08.02 |
Formulary
|
NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis |
| Palforzia |
03.04.02 |
Formulary
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
| Parathyroid Hormone |
06.06.01 |
Non Formulary
|
NICE TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) |
| Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Pegcetacoplan |
08.02.02 |
Formulary
|
NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200:Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon beta‑1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegunigalsidase alfa |
09.08.01 |
Formulary
|
NICE TA915: Pegunigalsidase alfa for treating Fabry disease |
| Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Pentoxifylline |
02.06.04 |
Formulary
|
NICE TA223- Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Perampanel |
04.08.01 |
Formulary
|
NICE NG217: Epilepsies in children, young people and adults |
| Pimecrolimus 1% |
13.05.03 |
Formulary
|
NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Ponesimod |
08.02.04 |
Formulary
|
NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317- Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
| Progestogen (micronised) vaginal capsules |
06.04.01.02 |
Formulary
|
NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management |
| Promethazine |
03.04.01 |
Formulary
|
NICE Evidence Summary: Rapid tranquillisation in mental health settings: promethazine hydrochloride |
| Promethazine injection |
04.01.01 |
Formulary
|
NICE NG10: Violence and aggression: short-term management in mental health, health and community settings |
| Propafenone |
02.03.02 |
Formulary
|
NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274: Ranibizumab for treating diabetic macular oedema |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal) |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria |
| Relugolix |
08.03.04.02 |
Formulary
|
NICE TA995: Relugolix for treating hormone-sensitive prostate cancer |
| Relugolix–estradiol–norethisterone acetate |
06.07.02 |
Formulary
|
NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids |
| Remdesivir |
05.03 |
Formulary
|
NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Ribavirin |
05.03.03 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.03 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Ribavirin |
05.03.03 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.03 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA200:Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Ribavirin |
05.03.03.02 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Rilpivirine hydrochloride |
05.03.01 |
Formulary
|
NICE TA757: Cabotegravir with rilpivirine for treating HIV-1 |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease |
| Rimegepant |
04.07.04.02 |
Formulary
|
NICE TA906: Rimegepant for preventing migraine |
| Risankizumab |
01.05.03 |
Formulary
|
NIE TA998: Risankizumab for treating moderately to severely active ulcerative colitis |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Risankizumab |
10.01.03 |
Formulary
|
NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Risankizumab |
01.05.03 |
Formulary
|
NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease |
| Risankizumab |
01.05.03 |
Formulary
|
NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis |
| Risdiplam |
10.02 |
Formulary
|
NICE TA755: Risdiplam for treating spinal muscular atrophy |
| Ritlecitinib |
13.05.03 |
Formulary
|
NICE TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over |
| Rituximab |
08.02.03 |
Formulary
|
NICE guidelines for Rituximab |
| Rituximab (rheumatology) |
10.01.03 |
Formulary
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban with aspirin |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivaroxaban with aspirin |
02.08.02 |
Formulary
|
NICE TA:919 Rimegepant for treating migraine |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA 244: Chronic obstructive pulmonary disease - roflumilast (only as part of a trial) |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Romiplostim for the treatment of chronic immune thrombocytopenia |
| Romosozumab |
06.06.02 |
Formulary
|
NICE TA791: Romosozumab for treating severe osteoporosis |
| Roxadustat |
09.01.01 |
Formulary
|
NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease |
| Sacubitril/valsartan |
02.05.05.02 |
Formulary
|
NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Semaglutide |
06.01.02.03 |
Formulary
|
NICE TA875: Semaglutide for managing overweight and obesity |
| Semaglutide |
04.05.01 |
Formulary
|
NICE TA875: Semaglutide for managing overweight and obesity |
| Setmelanotide |
06.07 |
Formulary
|
NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency |
| Setmelanotide |
06.07 |
Formulary
|
NICE HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome |
| Sildenafil |
02.06.04 |
Formulary
|
NICE ESOUM42: Digital ulcers: sildenafil |
| Sildenafil |
02.06.04 |
Formulary
|
NICE: Digital ulcers: sildenafil |
| Simvastatin and Ezetimibe Inegy |
02.12 |
Formulary
|
NICE TA 915:Pegunigalsidase alfa for treating Fabry diease |
| Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir |
05.03.03 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir and Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Sofosbuvir with Velpatasvir and Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Solriamfetol hydrochloride |
04.04 |
Formulary
|
NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy |
| Somatrogon |
06.05.01 |
Formulary
|
NICE TA863 Somatrogon for treating growth disturbance in children and young people aged 3 years and over |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
| Sotrovimab |
05.03 |
Formulary
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Spironolactone |
02.02.03 |
Formulary
|
NG106: Chronic heart failure in adults: diagnosis and management |
| Streptokinase |
02.10.02 |
Formulary
|
NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) |
| Tafamidis |
04.12 |
Formulary
|
NICE TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy |
| Teduglutide |
01.04.02 |
Formulary
|
NICE TA804: Teduglutide for treating short bowel syndrome |
| Tenecteplase |
02.10.02 |
Formulary
|
NICE TA52- Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Tenecteplase |
02.10.02 |
Formulary
|
NICE TA990: Tenecteplase for treating acute ischaemic stroke |
| Tenecteplase |
02.10.02 |
Formulary
|
NICE TA990: Tenecteplase for treating acute ischaemic stroke |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Terlipressin |
06.05.02 |
Formulary
|
NICE CG141: Acute upper gastrointestinal bleeding in over 16s: management |
| Tezacaftor–Ivacaftor |
03.07 |
Formulary
|
NICE TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis |
| Tezepelumab |
03.04.02 |
Formulary
|
NICE TA880 Tezepelumab for treating severe asthma |
| Theophylline |
03.01.03 |
Formulary
|
BNF: Theophylline |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Ticagrelor |
02.09 |
Formulary
|
NICE NG185: Acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236 - Ticagrelor for the treatment of acute coronary syndromes |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tirzepatide |
06.01.02.03 |
Formulary
|
NICE TA924: Tirzepatide for treating type 2 diabetes |
| Tobramycin |
05.01.04 |
Formulary
|
NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tocilizumab |
05.03 |
Formulary
|
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA920: Tofacitinib for treating active ankylosing spondylitis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Tralokinumab |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Tranexamic Acid |
02.11 |
Formulary
|
NICE NG39: Major trauma: assessment and initial management |
| Upadacitinib |
01.05.03 |
Formulary
|
NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis |
| Upadacitinib |
01.05.03 |
Formulary
|
NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease |
| Upadacitinib |
13.05.03 |
Formulary
|
NICE768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Upadacitinib |
13.05.03 |
Formulary
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA829: Upadacitinib for treating active ankylosing spondylitis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline for smoking cessation |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vericiguat |
02.05 |
Non Formulary
|
NICE TA731:Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) |
| Vernakalant |
02.03.02 |
Non Formulary
|
NICE TA675: Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) |
| Vibegron |
07.04.02 |
Formulary
|
NICE TA999: Vibegron for treating symptoms of overactive bladder syndrome |
| Voclosporin |
08.02.02 |
Formulary
|
NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis |
| Volanesorsen |
02.12 |
Formulary
|
NICE HST13: Volanesorsen for treating familial chylomicronaemia syndrome |
| Voretigene neparvovex |
11.11 |
Formulary
|
NICE: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes |
| Voxelotor |
09.01.03 |
Formulary
|
NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease |
| Vutrisiran |
09.08.01 |
Formulary
|
NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
